Abstract
Background: Accumulating evidence suggests that the non-intoxicating cannabinoid compound cannabidiol (CBD) may have antipsychotic and anxiolytic properties, and thus may be a promising new agent in the treatment of psychotic and anxiety disorders. However, the neurobiological substrates underlying the potential therapeutic effects of CBD are still unclear. The aim of this systematic review is to provide a detailed and up-to-date systematic literature overview of neuroimaging studies that investigated the acute impact of CBD on human brain function. Methods: Papers published until May 2020 were included from PubMed following a comprehensive search strategy and pre-determined set of criteria for article selection. We included studies that examined the effects of CBD on brain function of healthy volunteers and individuals diagnosed with a psychiatric disorder, comprising both the effects of CBD alone as well as in direct comparison to those induced by ∆9-tetrahydrocannabinol (THC), the main psychoactive component of Cannabis. Results: One-ninety four studies were identified, of which 17 met inclusion criteria. All studies investigated the acute effects of CBD on brain function during resting state or in the context of cognitive tasks. In healthy volunteers, acute CBD enhanced fronto-striatal resting state connectivity, both compared to placebo and THC. Furthermore, CBD modulated brain activity and had opposite effects when compared to THC following task-specific patterns during various cognitive paradigms, such as emotional processing (fronto-temporal), verbal memory (fronto-striatal), response inhibition (fronto-limbic-striatal), and auditory/visual processing (temporo-occipital). In individuals at clinical high risk for psychosis and patients with established psychosis, acute CBD showed intermediate brain activity compared to placebo and healthy controls during cognitive task performance. CBD modulated resting limbic activity in subjects with anxiety and metabolite levels in patients with autism spectrum disorders. Conclusion: Neuroimaging studies have shown that acute CBD induces significant alterations in brain activity and connectivity patterns during resting state and performance of cognitive tasks in both healthy volunteers and patients with a psychiatric disorder. This included modulation of functional networks relevant for psychiatric disorders, possibly reflecting CBD’s therapeutic effects. Future studies should consider replication of findings and enlarge the inclusion of psychiatric patients, combining longer-term CBD treatment with neuroimaging assessments.
Highlights
There has been a growing interest in cannabidiol (CBD) as a therapeutic substance, due to its putative antipsychotic, anxiolytic and anti-craving effects (Iseger and Bossong, 2015; Rohleder et al, 2016; Batalla et al, 2019)
An increasing number of neuroimaging studies have been performed to examine the human neural mechanisms underlying the effects of CBD. Some of these studies have been included in excellent reviews that describe the impact of cannabis on human brain function in a broader context (Martín-Santos et al, 2010; Bhattacharyya et al, 2012a; Batalla et al, 2014; Weinstein et al, 2016), the aim of the current review is to provide a systematic and up-to-date overview of neuroimaging studies that investigated the effects of CBD on human brain function
12 studies reported the acute effects of CBD compared to placebo (Crippa et al, 2004; Borgwardt et al, 2008; Bhattacharyya et al, 2009; Fusar-Poli et al, 2009; Fusar-Poli et al, 2010) or compared to the main psychoactive compound delta-9tetrahydrocannabinol (THC) (Bhattacharyya et al, 2010; Winton-Brown et al, 2011; Bhattacharyya et al, 2012b; Bhattacharyya et al, 2015; Freeman et al, 2018; Grimm et al, 2018; Wall et al, 2019)
Summary
There has been a growing interest in cannabidiol (CBD) as a therapeutic substance, due to its putative antipsychotic, anxiolytic and anti-craving effects (Iseger and Bossong, 2015; Rohleder et al, 2016; Batalla et al, 2019). Since most conventional treatments in psychiatry, such as antipsychotics and antidepressants, are associated with limited response rates and adverse events that often limit tolerability and adherence (Blessing et al, 2015; Samara et al, 2019), there is an urgent need for developing novel pharmaceutical treatments (Leucht et al, 2013; Blessing et al, 2015; Lally and MacCabe, 2015) In this regard, CBD has been proposed as novel therapeutic compound in several psychiatric disorders, such as psychosis (Iseger and Bossong, 2015; Batalla et al, 2019), anxiety disorders (Blessing et al, 2015), substance use disorders (Chye et al, 2019; Freeman et al, 2020) and autism spectrum disorders (Poleg et al, 2019; Fusar-Poli et al, 2020). The aim of this systematic review is to provide a detailed and up-todate systematic literature overview of neuroimaging studies that investigated the acute impact of CBD on human brain function
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
